FDA OKs new use for Melinta's Baxdela; shares down 26% premarket on potential capital raise

FDA OKs new use for Melinta's Baxdela; shares down 26% premarket on potential capital raise

Source: 
Seeking Alpha
snippet: 

The FDA approves Melinta Therapeutics' (NASDAQ:MLNT) BAXDELA (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP).